| Authors: |
Jespersen MS; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; National Center for Cancer Immune Therapy, CCIT-DK. Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Electronic address: Mette.syberg.jespersen@regionh.dk., Palshof JAE; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Fristrup N; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Jensen NV; Department of Oncology, Odense University Hospital, Odense, Denmark., Henriksen JR; Department of Oncology, Odense University Hospital, Odense, Denmark., Iversen ABB; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Steen SG; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Andersen M; Drug Design and Pharmacology, University of Copenhagen, Copenhagen Ø, Denmark., Madsen K; National Center for Cancer Immune Therapy, CCIT-DK. Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Svane IM; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; National Center for Cancer Immune Therapy, CCIT-DK. Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Darras AKM; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. |